A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic...

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Acinar-to-ductal metaplasia (ADM) driven by KRAS mutations is a critical early event in pancreatic ductal adenocarcinoma (PDAC) development.
• The role of programmed cell death (PCD) pathways in KRAS-driven ADM and subsequent PDAC progression is not fully understood.

Purpose of the Study:

• To investigate the involvement of cell death regulators in KRAS-driven ADM.
• To identify molecular mechanisms that prevent the elimination of transdifferentiated cells during PDAC initiation.
• To evaluate the therapeutic potential of targeting key regulators of cell survival in PDAC.

Main Methods:

• Utilized transgenic mouse models and primary cell and organoid cultures.
• Examined the expression and activity of programmed cell death (PCD) regulators during KRAS-driven ADM.
• Investigated the role of transforming growth factor-beta-activated kinase 1 (TAK1) in regulating cell survival and PCD.
• Assessed the effects of pharmacological TAK1 inhibition on patient-derived PDAC organoids.

Main Results:

• Key regulators of PCD are upregulated during KRAS-driven ADM, priming cells for death.
• Transforming growth factor-beta-activated kinase 1 (TAK1) was found to inhibit receptor-interacting protein kinase 1 (RIPK1)-mediated apoptosis and necroptosis, thereby preventing the clearance of transdifferentiated cells.
• Pharmacological inhibition of TAK1 successfully induced PCD in patient-derived PDAC organoids.
• TAK1 inhibition-induced cell death did not trigger a significant injury-associated inflammatory response.

Conclusions:

• TAK1 plays a crucial role in suppressing spontaneous PCD during ADM, supporting cellular plasticity necessary for PDAC development.
• Targeting TAK1 represents a promising therapeutic strategy for PDAC prevention and treatment by inducing PCD without eliciting major inflammation.